What We Do

Icentia is a combined medical devices and service company based in Canada. It aims at providing a line of innovative medical testing solutions for healthcare institutions. Thanks to a strong understanding of the institutional healthcare environment along with important partnerships with medical specialists, Icentia is able to offer valuable solutions for major problems in the fields of medical testing.

Our mission is to help healthcare institutions become more efficient by providing unique solutions easing the process of medical testing.

Icentia has put together a seasoned management team with solid expertise in medical device development, global supply chain management, and operations in a regulated environment.

Icentia benefits from a collaboration with the Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ) for the testing of its products. IUCPQ is one of the largest center for cardiology and pulmonology in eastern Canada.

Our Corporate Values

What Drives our Decisions

These values define us as a company not only for our clients and partners, but also for patients who benefit from our technologies. Our values describe who we are and how we do things.

Our Leadership Team

martin leblanc
CHAIRMAN OF THE BOARD

Martin LeBlanc is co-founder and CEO of Caprion Biosciences, a Montreal-based company founded in 2000 offering specialized laboratory research services in the fields of proteomics, genomics, immunohistochemistry and immune surveillance for more than a hundred customers in the pharmaceutical and biotechnology industries.

He is also Chairman of the Board of Montréal InVivo and a member of several boards of private companies and non-profit organizations. Prior to Caprion, he was a management consultant for McKinsey & Company and a lead entrepreneur in another biotechnology company, Advanced Bioconcept.

Martin LeBlanc holds a bachelor's degree in economics from the University of Moncton and a master's degree in economics and political science from Oxford University where he was a Rhodes Scholar.

PIERRE PAQUET
CHIEF EXECUTIVE OFFICER and member of the board

Pierre serves as the Chief Executive Officer since 2012. Prior to joining Icentia, Pierre was Director of Product Management for the Innovation Center at CareFusion, a San Diego based global corporation serving the healthcare industry. Previously, he was Director of Implantable Devices in the field of active neurological implants at Victhom Human Bionics.

Pierre holds a B.S. in mechanical engineering from Laval University and a M.B.A. in management of technology from the Swiss Federal Institute of Technology in Lausanne, Switzerland.

Sean Karamchandani
member of the board

Sean Karamchandani is Investment Director in the Canadian venture capital arm of Crédit Mutuel Equity, a private equity subsidiary of Crédit Mutuel Alliance Fédérale, one of France’s largest banking organizations.

With 10 years of experience in healthcare investment in both venture and growth-equity Sean began his career as a management consultant to large healthcare institutions. He was then a partner with Persistence Capital Partners, a Canadian healthcare focused private-equity fund. Sean has dedicated his career to accelerating healthcare service, device, product, and pharmaceutical companies. .

Sean holds a bachelor’s degree in economics from Harvard University and an MBA from Columbia Business School in New York.

Louis Laflamme
member OF THE BOARD

Louis Laflamme is President, CEO and Director of Opsens, a company working in interventional cardiology by offering on world markets an optical pressure measurement guide wire (OptoWire) which aims to improve the clinical results of patients with coronary disease. He has also held various senior management positions in biotechnology and software technology companies. Mr. Laflamme has been a member of the Quebec Chartered Professional Accountants Order since 2001. He obtained a bachelor's degree in business administration from Laval University in 1998.

RICHARD BORDELEAU
member OF THE BOARD

Richard Bordeleau has helped several innovative companies grow in international markets. After having worked as a consultant with a number of innovative companies, he held executive positions at Laboratoires Aeterna from 1994 to 1999 where he signed several partnerships with large pharmaceutical companies and played a key role in project financing. He was then president at Atrium Innovations, launching specialty chemicals and nutritional products on an international scale between 2000 and 2007.

In September 2007, he became a shareholder and director of BioCad Medical. Since the sale of BioCad to Nobel Biocare in 2009, he has been an angel investor for startups working in different sectors. He is also president of Fonds InnovExport, a $30 million fund dedicated to financing businesses developing innovative products for international markets.

Richard Bordeleau has a bachelor’s degree in business administration from the Université Laval.

YANNICK LE DEVEHAT
CHIEF TECHNOLOGY OFFICER

Yannick is a seasoned executive and entrepreneur with extensive experience in high-tech product design and manufacturing. During a 5-year posting in Tokyo, Japan, Yannick managed the Telecom and Smart Card Business Unit of TÜV SÜD, one of the world's largest product certification agencies. Since then, he has been active in the management of new tech-ventures, bringing in a wealth of experience in technology, supply chain management, and contract negotiation at an international level.

Yannick graduated with a B.S. degree in electrical engineering from Laval University.